• Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Home
  • About
  • BCPS
  • Medicine and Media
  • Pharmacogenomics
  • Podcast
Digital PharmD

Digital PharmD

Informatics in Pharmacy

Multiple Sclerosis

August 13, 2018 By Dr. G, PharmD

Print Friendly, PDF & Email

Acute Relapses:

  • Methylprednisone 1g/day in divided doses for 3-5 days.
  • Oral prednisone 1250 mg every other day for 5 days
  • Intravenous adrenocortical hormones.

DMARDs-

  1. Alemtuzumab – Can cause thyroid disorder, infusion reactions, increased infections (screen for herpes and TB before giving), may risk some cancers, vaccinate 6 weeks prior to therapy, avoid live vaccines during treatment.
  2. B – interferon – flu-like symptoms, injection site problems
  3. Dimethyl fumarate – GI and skin reactions
  4. Glatiramer acetate – injection site reactions, chest pain, shortness of breath,
  5. Fingolimod – Contraindicated in mi, unstable angina and stroke, heart failure class III/ IV monitor for bradycardia, avoid he vaccines.
  6. mitoxantrone – only second line due to toxicity. Can cause leukemia-like disease
  7. Natalizumab – relapsing forms, only through special program due to leukoencephalopathy risk.
  8. Teriflunomide – Secondary, hepatotoxicity, neutropenia, increased infection risk.

Fatigue: non-pharmacologic (rest, sleep management, cooling) or amantadine or methylphenidate
Spasticity: Baclofen or tizanidine
Walking Impairment: Dalfampridine (K+ Channel Blocker): may cause seizures, UTI, insomnia
Pseudobulbar affect: Dextromethorphan/Quinidine

Filed Under: Uncategorized

Primary Sidebar

Newsletter

More to See

COVID-19 mRNA EUA Vaccine FAQs

December 29, 2020 By Dr. G, PharmD

What Makes a Good Vaccine? (Part 1)

October 20, 2020 By Dr. G, PharmD

Tags

acid base acidosis acute coronary syndrome alkalosis analgesics anaphylaxis aortic dissection arrhythmia bcps Beta-Blockers biostatistics blood pressure cardiac markers CHA2DS2-VasC cocaine COVID-19 diabetes diabetes inspidius heart failure Heparin hypersensitivity hypertension hypovolemic shock intubation ionotropes journal club lipids LMWH medication safety morphine conversions myocardial infarction needs work NOAC NSTEMI obstructive shock pharmacoeconomics pheochromocytoma pressors reference materials right mi sedation septic shock shock STEMI Updated 2020

Footer

Medical Disclaimer

The medical information on this website is provided “as is” without any representations or warranties, express or implied. GoPharmD makes no representations or warranties in relation to the medical information on this website.

GoPharmD does not warrant that:

  • the medical information on this website will be constantly available, or available at all; or
  • the medical information on this website is complete, true, accurate, up-to-date, or non-misleading.
  • You must not rely on the information on this website as an alternative to medical advice from your doctor or other professional healthcare provider.
  • If you have any specific questions about any medical matter you should consult your doctor or other professional healthcare provider.

Recent

  • Johnson and Johnson Coronavirus EUA Vaccine FAQ
  • COVID-19 mRNA EUA Vaccine FAQs
  • What Makes a Good Vaccine? (Part 1)
  • COPD and Bronchitis
  • Asthma

Search

Tags

acid base acidosis acute coronary syndrome alkalosis analgesics anaphylaxis aortic dissection arrhythmia bcps Beta-Blockers biostatistics blood pressure cardiac markers CHA2DS2-VasC cocaine COVID-19 diabetes diabetes inspidius heart failure Heparin hypersensitivity hypertension hypovolemic shock intubation ionotropes journal club lipids LMWH medication safety morphine conversions myocardial infarction needs work NOAC NSTEMI obstructive shock pharmacoeconomics pheochromocytoma pressors reference materials right mi sedation septic shock shock STEMI Updated 2020